Cargando…
Impact of PD‐L1, transforming growth factor‐β expression and tumor‐infiltrating CD8(+) T cells on clinical outcome of patients with advanced thymic epithelial tumors
BACKGROUND: Advanced thymic epithelial tumors (TETs) are indolent and poorly responsive to chemotherapy. PD‐1/PD‐L1 inhibitors have shown remarkable clinical benefit in several cancers; however, many immunomodulatory molecules have been identified that affect the immune response. This study examined...
Autores principales: | Duan, Jianchun, Liu, Xidong, Chen, Han, Sun, Yu, Liu, Yiqiang, Bai, Hua, Wang, Jie |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley & Sons Australia, Ltd
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6209778/ https://www.ncbi.nlm.nih.gov/pubmed/30168897 http://dx.doi.org/10.1111/1759-7714.12826 |
Ejemplares similares
-
PD-L1 Expression and Tumor-Infiltrating Lymphocytes in Thymic Epithelial Neoplasms
por: Higuchi, Rumi, et al.
Publicado: (2019) -
Significance of tumor mutation burden and immune infiltration in thymic epithelial tumors
por: Wang, Zi‐Ming, et al.
Publicado: (2021) -
Immunotherapeutic potential of CD4 and CD8 single-positive T cells in thymic epithelial tumors
por: Yamamoto, Yoko, et al.
Publicado: (2020) -
The Expression of PD-L1 and B7-H4 in Thymic Epithelial Tumor and Its Relationship With Tumor Immune-Infiltrating Cells
por: Yan, Xiaotian, et al.
Publicado: (2021) -
Expression of PD-L1 and other immunotherapeutic targets in thymic epithelial tumors
por: Arbour, Kathryn C., et al.
Publicado: (2017)